Table 1.
Characteristic | Training dataset (N = 61) | Testing dataset (N = 25) | P value | External dataset (N = 26) |
---|---|---|---|---|
Age,median (range)years | 50(33–74) | 51(40–58) | 0.970 | 52(40–74) |
FIGO stage, No. (%) | ||||
Ia | 18(29.50) | 4(16.00) | 5(19.23) | |
Ib | 26(42.60) | 10(40.00) | 12(46.15) | |
IIa | 17(27.90) | 11(44.00) | 9(34.62) | |
Tumor grade, No. (%) | 0.085 | |||
Well differentiate | 14(23.00) | 6(24.00) | 6(23.08) | |
Moderately differentiate | 29(47.50) | 17(68.00) | 15(57.69) | |
Poorly differentiate | 18(29.50) | 2(8.00) | 5(19.23) | |
Depth of cervical stromal tumor invasion, No. (%) | 0.605 | |||
≥ 1/2 | 43(70.50) | 19(76.00) | 21(80.77) | |
<1/2 | 18(29.50) | 6(24.00) | 5(19.23) | |
LVSI, No. (%) | 0.921 | |||
Yes | 30(49.20) | 12(48.00) | 15(57.69) | |
No | 31(50.80) | 13(52.00) | 11(42.31) | |
COX-2 expression No. (%) | 0.400 | |||
Negative or Weak-Positive | 28(45.90) | 11(44.00) | 11(42.31) | |
Moderate-Positive | 22(36.10) | 12(48.00) | 10(38.46) | |
Strong-Positive | 11(18.00) | 2(8.00) | 5(19.23) | |
TNC expression No. (%) | 0.975 | |||
Negative or Weak-Positive | 40(65.60) | 17(68.00) | 19 (73.08) | |
Moderate-Positive | 16(26.20) | 6(24.00) | 6(23.08) | |
Strong-Positive | 5(8.20) | 2(8.00) | 1(3.85) |
FIGO International Federation of Gynecology and Obstetrics, LVSI lymphovascular space invasion, COX-2 cyclooxygenase-2, TNC tenascin-C